DRREDDY:NSE
Dr Reddy's Laboratories Ltd
1.199,80 INR
arrow_upward
+1,68%(+19,80) 1D
9. lis, 15:30:00 GMT+5:30 · INR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za DRREDDY...
Otvori
1.180,00 INR
Najviša
1.200,80 INR
Najniža
1.172,00 INR
Trž. kap.
999,42 mlr.
Prosj. kol.
1,81 mil.
Količina
1,51 mil.
Dividenda
0,67 %
Kvartalna dividenda
2,00 INR
Datum nakon isplate dividende
10. srp 2026.
P/E omjer
31,03
52-tjed. najviša
1.414,90 INR
52-tjed. najniža
1.101,00 INR
EPS
38,67 INR
Dionice u optjecaju
166,06 mil.
Broj djelatnika
28 tis.
Otvori
1.180,00 INR
Najviša
1.200,80 INR
Najniža
1.172,00 INR
Trž. kap.
999,42 mlr.
Prosj. kol.
1,81 mil.
Količina
1,51 mil.
Dividenda
0,67 %
Kvartalna dividenda
2,00 INR
Datum nakon isplate dividende
10. srp 2026.
P/E omjer
31,03
52-tjed. najviša
1.414,90 INR
52-tjed. najniža
1.101,00 INR
EPS
38,67 INR
Dionice u optjecaju
166,06 mil.
Broj djelatnika
28 tis.
Povezane dionice
Vijesti
Iz web-izvora i od partnera za vijesti
TipRanks
·
prije 22 sata
Dr. Reddy’s Receives Two-Observation USFDA Form 483 After PAI at FTO-11
TipRanks
·
prije 2 dana
Dr. Reddy’s Sets October 23 Date for Q2 FY27 Results and Global Earnings Call
Stock Titan
·
prije 2 dana
A 10 a.m. ET earnings call is scheduled for October 23 at Dr. Reddy’s (RDY).
Profil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Dr Reddy's Laboratories Ltd – informacije
Glavni izvršni direktorErez Israeli
Zaposlenici27,5 tis.
Osnovano1984
SjedišteHiderabad, Andhra Pradesh, Indija
Sektor-
Web-lokacijadrreddys.com